Last reviewed · How we verify
Flu-Mel
Flu-Mel is an antiviral medication that targets the influenza virus.
Flu-Mel is an antiviral medication that targets the influenza virus. Used for Treatment of uncomplicated influenza A and B in patients 2 weeks of age and older.
At a glance
| Generic name | Flu-Mel |
|---|---|
| Also known as | Fludara-Alkaran |
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Neuraminidase inhibitor |
| Target | Neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Flu-Mel works by inhibiting the neuraminidase enzyme, which is essential for the release of new viral particles from infected cells. This mechanism of action helps to reduce the spread of the virus within the body, thereby alleviating symptoms and shortening the duration of illness.
Approved indications
- Treatment of uncomplicated influenza A and B in patients 2 weeks of age and older
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (PHASE2)
- Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation (PHASE2)
- Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (PHASE2)
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |